Vor Biopharma (VOR) Stock Forecast & Price Target

Compare

958 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VOR Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Vor

Biopharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VOR Stock 12 Month Forecast

Average Price Target

$36.40

▲(165.50% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $36.40 with a high forecast of $55.00 and a low forecast of $9.00. The average price target represents a 165.50% change from the last price of $13.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","56":"$56","16.25":"$16.25","29.5":"$29.5","42.75":"$42.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,16.25,29.5,42.75,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.68,11.32,14.96,18.6,22.240000000000002,25.88,29.52,33.16,36.8,40.44,44.08,47.72,51.36,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.68,9.88923076923077,12.098461538461539,14.307692307692307,16.516923076923078,18.726153846153846,20.935384615384613,23.144615384615385,25.353846153846153,27.56307692307692,29.77230769230769,31.98153846153846,34.19076923076923,{"y":36.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.68,7.781538461538461,7.883076923076922,7.984615384615385,8.086153846153845,8.187692307692307,8.28923076923077,8.39076923076923,8.492307692307692,8.593846153846155,8.695384615384615,8.796923076923077,8.898461538461538,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$55.00

Average Price Target$36.40

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jack Allen

Robert W. Baird

$64→$46

Buy

235.52%

Upside

Reiterated

12/23/25

Vor Bio price target lowered to $46 from $64 at BairdVor Bio price target lowered to $46 from $64 at Baird

Anupam Rama

J.P. Morgan

$43→$40

Buy

191.76%

Upside

Reiterated

12/18/25

Vor Bio price target lowered to $40 from $43 at JPMorganVor Bio price target lowered to $40 from $43 at JPMorgan

Yaron Werber

TD Cowen

Buy

―

Initiated

12/17/25

Vor Biopharma (VOR) Gets a Buy from TD Cowen

Martin Fan

Wedbush

Hold

-34.35%

Downside

Initiated

11/25/25

Vor Biopharma (VOR) Gets a Hold from Wedbush

Swayampakula Ramakanth

H.C. Wainwright

$32

Buy

133.41%

Upside

Reiterated

11/19/25

H.C. Wainwright Sticks to Its Buy Rating for Vor Biopharma (VOR)

Stephen Willey

Stifel Nicolaus

$55

Buy

301.17%

Upside

Reiterated

11/10/25

Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)

Umer Raffat

Evercore ISI

Buy

―

Reiterated

05/12/25

Vor Biopharma (VOR) Receives a Buy from Evercore ISI

Silvan Tuerkcan

Citizens JMP

Hold

―

Downgraded

05/09/25

Vor Bio downgraded to Market Perform from Outperform at Citizens JMPVor Bio downgraded to Market Perform from Outperform at Citizens JMP

Justin Walsh

JonesTrading

Hold

―

Downgraded

05/08/25

JonesTrading downgrades Vor Biopharma (VOR) to a Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jack Allen

Robert W. Baird

$64→$46

Buy

235.52%

Upside

Reiterated

12/23/25

Vor Bio price target lowered to $46 from $64 at BairdVor Bio price target lowered to $46 from $64 at Baird

Anupam Rama

J.P. Morgan

$43→$40

Buy

191.76%

Upside

Reiterated

12/18/25

Vor Bio price target lowered to $40 from $43 at JPMorganVor Bio price target lowered to $40 from $43 at JPMorgan

Yaron Werber

TD Cowen

Buy

―

Initiated

12/17/25

Vor Biopharma (VOR) Gets a Buy from TD Cowen

Martin Fan

Wedbush

Hold

-34.35%

Downside

Initiated

11/25/25

Vor Biopharma (VOR) Gets a Hold from Wedbush

Swayampakula Ramakanth

H.C. Wainwright

$32

Buy

133.41%

Upside

Reiterated

11/19/25

H.C. Wainwright Sticks to Its Buy Rating for Vor Biopharma (VOR)

Stephen Willey

Stifel Nicolaus

$55

Buy

301.17%

Upside

Reiterated

11/10/25

Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)

Umer Raffat

Evercore ISI

Buy

―

Reiterated

05/12/25

Vor Biopharma (VOR) Receives a Buy from Evercore ISI

Silvan Tuerkcan

Citizens JMP

Hold

―

Downgraded

05/09/25

Vor Bio downgraded to Market Perform from Outperform at Citizens JMPVor Bio downgraded to Market Perform from Outperform at Citizens JMP

Justin Walsh

JonesTrading

Hold

―

Downgraded

05/08/25

JonesTrading downgrades Vor Biopharma (VOR) to a Hold

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vor Biopharma

1 Month

xxx

Success Rate

7/16 ratings generated profit

Average Return

-0.35%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 43.75% of your transactions generating a profit, with an average return of -0.35% per trade.

3 Months

xxx

Success Rate

6/16 ratings generated profit

Average Return

-16.98%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 37.50% of your transactions generating a profit, with an average return of -16.98% per trade.

1 Year

Stephen WilleyStifel Nicolaus

Success Rate

1/16 ratings generated profit

Average Return

-61.06%

reiterated a buy rating last month

Copying Stephen Willey's trades and holding each position for 1 Year would result in 6.25% of your transactions generating a profit, with an average return of -61.06% per trade.

2 Years

xxx

Success Rate

1/16 ratings generated profit

Average Return

-76.76%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 6.25% of your transactions generating a profit, with an average return of -76.76% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VOR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VOR has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VOR average Analyst price target in the past 3 months is 36.40.

Each month's total comprises the sum of three months' worth of ratings.

VOR Financial Forecast

VOR Earnings Forecast

Next quarter’s earnings estimate for VOR is -$1.64 with a range of -$4.86 to -$0.44. The previous quarter’s EPS was -$121.63. VOR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VOR has Performed in-line its overall industry.

No data currently available

VOR Sales Forecast

Next quarter’s sales forecast for VOR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VOR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VOR has Performed in-line its overall industry.

VOR Stock Forecast FAQ

What is VOR’s average 12-month price target, according to analysts?

Based on analyst ratings, Vor Biopharma’s 12-month average price target is 36.40.

What is VOR’s upside potential, based on the analysts’ average price target?

Vor Biopharma has 165.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VOR a Buy, Sell or Hold?

Vor Biopharma has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Vor Biopharma’s price target?

The average price target for Vor Biopharma is 36.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $9.00. The average price target represents 165.50% Increase from the current price of $13.71.

What do analysts say about Vor Biopharma?

Vor Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of VOR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vor Biopharma (VOR) Stock Forecast & Price Target

VOR Analyst Ratings

VOR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vor Biopharma

VOR Analyst Recommendation Trends

VOR Financial Forecast

VOR Earnings Forecast

VOR Sales Forecast

VOR Stock Forecast FAQ

Detailed List of Analyst Forecasts